365 / 1266
WBRT + gefitinib or temozolomide
• Gefitinib: median OS
6.3
months
• Temozolomide: median OS
4.9
months
• Fatigue as major side effect
WBRT and SRS + erlotinib or temozolomide in patients
with < 3 brain mets
• WBRT and SRS: median OS
13.4
months
• Addition of temozolomide: median OS
6.3
months
• Addition of erlotinib: median OS
6.1
months
• Increased toxicity in the gefitinib and temozolomide arm
Pesce et al. Eur J Cancer 2012
Sperduto et al. Int J Radiat Oncol Biol Phys 2013
(probably) not prolong survival